Angiodynamics receives fda breakthrough device designation for the angiovac system for the non-surgical removal of right heart vegetation

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that the u.s. food and drug administration (fda) has granted breakthrough device designation for the company's angiovac system for the proposed indications for use to include the non-surgical removal of vegetat.
ANGO Ratings Summary
ANGO Quant Ranking